Care of depression in the elderly: Comparative pharmacokinetics of SSRIs

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 5, 1998, Pages

  Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Antidepressants; Cytochrome P 450; Elderly depressive patients; Pharmacogenetics; Pharmacokinetics; Somatic disease; SSRIs

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CONFERENCE PAPER; DEPRESSION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ELDERLY CARE; ENANTIOMER; HUMAN; PRIORITY JOURNAL; STEREOSPECIFICITY;

EID: 0031688708     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199809005-00008     Document Type: Conference Paper

References (59)

1. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, and Beasley CM (1997). Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 154:963-969.
2. Anstey K and Brodaty H (1995). Antidepressants and the elderly: double-blind trials 1987-1992. Int J Geriatr Psychiatry 10:265-279.
3. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, and Lemberger L (1984). Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36:138-144.
4. Baumann P and Rochat B (1995). Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10 (suppl 1):15-21.
5. Baumann P (1996a). Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444-469.
6. Baumann P (1996b). Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 11 (suppl 1):5-11.
7. Baumann P and Larsen F (1995). The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287-295.
8. Baumann P, Eap CB, de Mendonça Lima CA, Zullino D (1998). Characteristics of psychotropic drug metabolism in geriatric patients. In Mental Disorders in the Elderly: New Therapeutic Approaches. (Brunello N, Lager SZ, Racagni G, eds) Karger, Basel: International Academy of Biomedical Drug Research 13:159-170.
9. Bayer AJ, Roberts NA, Allen EA, Horan M, Routledge PA, Swift CG, Byrne MM, Clarkson A, Zussman BD (1989). The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 80 (suppl 350):85-86.
10. Bertilsson L, Dahl M-L, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, Lundqvist H, and Ingelman-Sundberg M (1993). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63.
11. Bloomer JC, Woods FR, Haddock RE, Lennard MS, and Tucker GT (1992). The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33:521-523.
12. Brøsen K (1996a). Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 11 (suppl 1):23-27.
13. Brøsen K (1996b). Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monitor 18:393-396.
14. Catterson ML, Preskorn SH, Martin RL (1997). Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psych Clin N Am 20:205-218.
15. de Vries MH, Raghoebar M, Mathlener IS, van Harten J (1992). Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monitor 14:493-498.
16. Démolis J-L, Angebaud P, Grangé J-D, Coates P, Funck-Brentano C, and Jaillon P (1996). Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 42:394-397.
17. Feighner JP and Cohn JB (1985). Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 46:20-25.
18. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, and Bŕsen K (1997). The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine. Eur J Clin Pharmacol 52 (suppl):A127/379 [Abstract].
19. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B (1997). Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 33:109-112.
20. Fredricson Overø K, Toft B, Christophersen L, Gylding-Sabroe JP (1985). Kinetics of citalopram in elderly patients. Psychopharmacology 86:253-257.
21. Gunasekara NS, Noble S and Benfield P (1998). Paroxetine An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 55:85-120.
22. Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, and Lebel M (1996). The disposition of fluoxetine but not of sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Therapeutics 60:512-521.
23. Hyttel J, Bøgesø KP, Perregaard J, and Sanchez C (1992). The pharmacological effect of citalopram resides in the (S)-(+)- enantiomer. Short communication. J Neur Transmiss Gen Sect 88:157-160.
24. Kasper S, Dötsch M, Kick H, Vieira A, and Möller HJ (1993). Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 3:13-21.
25. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, et al. (1997). Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280:927-933.
26. Kragh-Sørensen P, Fredricson Overø K, Petersen OL, Jensen K, Parnas W (1981). The kinetics of citalopram: Single and multiple dose studies in man. Acta Pharmacol Toxicol 48:53-60.
27. Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Mäki-Ikola O, et al. (1997). Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 20 (suppl 5):419-433.
28. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, and Aronoff GR (1985). Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 46:14-19.
29. Menting JEA, Honig A, Verhey FRJ, Hartmans M, Rozendaal N, de Vet HCW, and van Praag HM (1996). Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 11:165-175.
30. Meyer UA and Zanger UM (1997). Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 37:269-296.
31. Norman TR (1993). Pharmacokinetics aspects of antidepressant treatment in the elderly. Prog Neuropsychopharmacol Biol Psychiatry 17:329-344.
32. Perry CM and Benfield P (1997). Sertraline -An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drug 7:480-500.
33. Pollock BG, Perel JM, Altieri LP, Kirshner M, Fasiczka AL, Houck PR, and Reynolds CF III (1992). Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 28:163-168.
34. Preskorn SH (1993). Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 94 (suppl 5A):2S-12S.
35. Rochat B, Amey M, Gillet M, Meyer UA, and Baumann P (1997). Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1-10.
36. Rochat B, Kosel M, Boss G, Testa B, Gillet M, and Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol (in press).
37. Ronfeld RA, Tremaine LM, Wilner KD (1997). Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (suppl 1):23-30.
38. Rudorfer MV, Manji HK, and Potter WZ (1994). Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety 10:18-46.
39. Ryan DE and Levin W (1992). Purification and characterization of hepatic microsomal cytochrome P-450. In Pharmacogenetics of Drug Metabolism. (Kalow W, ed.) New York, USA: Pergamon Press Inc. pp. 453-547.
40. Salzman C (1993). Pharmacologic treatment of depression in the elderly. J Clin Psychiatry 54 (suppl):23-28.
41. Schenker S, Bergstrom RF, Wolen RL, and Lemberger L (1988). Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 44:353-359.
42. Schneider LS, Martinez RA, Lebowitz BD (1993). Clinical psychopharmacology research in geriatrics: an agenda for research. Int J Geriatr Psychiatry 8:89-93.
43. Siegmund W, Hanke W, Zschiesche M, Franke G, Biebler KE, and Wilke A (1990). N-acetylation and debrisoquine type oxidation polymorphism in Caucasians - with reference to age and sex. Int J Clin Pharmacol Ther Toxicol 28:504-509.
44. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, et al. (1992a). The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278-287.
45. Sindrup SH, Brøsen K, and Gram LF (1992b). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:288-295.
46. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Fredricson Overø K, and Gram LF (1993). Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monitor 15:11-17.
47. Sommi RW, Crismon ML, Bowden CL (1987). Evaluations of new drugs. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 7:1-15.
48. Spigset O, Carleborg L, Hedenmalm K, and Dahlqvist R (1995). Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 58:399-403.
49. Spigset O, Granberg K, Hägg S, Norström A, and Dahlqvist R (1997). Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 52:129-133.
50. Uehlinger C, Nil R, Amey M, Baumann P, Dufour H (1995). Citalopram-lithium combination treatment of elderly depressed patients: a pilot study. Int J Geriatr Psychiatry 10:281-287.
51. Van Harten J, Duchier J, Devissaguet JP, Van Bemmel P, De Vries MH, and Raghoebar M (1993). Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 24:177-182.
52. Vedak CS, Jampala VC (1993). Pharmacokinetics of psychotropic drugs in geriatric patients. In Pharmacokinetics and Therapeutic Monitoring of Psychiatric Drugs. (Musa MN ed.) Sprinsfield, Illinois, USA: Charles C. Thomas. pp. 30-40.
53. Volz HP and Möller HJ (1994). Antidepressant drug therapy in the elderly - a critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry 27:93-100.
54. Von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI (1995). Psychotropic drug metabolism in old age - Principles and problems of assessment. In Psychopharmacology: The Fourth Generation of Progress. (Bloom FE, Kupfer DJ eds.). New York, USA: Raven Press Ltd. pp. 1461-1469.
55. Walker Z and Katona CLE (1997). Depression in elderly people with physical illness. In Depression and Physical Illness. (Robertson MM and Katona CLE eds.) Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons Ltd. pp. 169-181.
56. Weyler W, Hsu YPP, Breakefield XO (1992). Biochemistry and genetics of monoamine oxidase. In Pharmacogenetics of Drug Metabolism. (Kalow W ed.) New York, USA: Pergamon Press Inc. pp. 333-366.
57. Wilde MI, Plosker GL, Benfield P (1993). Fluvoxamine -An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 46:895-924.
58. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, and Robertson DW (1993). Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 8:337-344.
59. Wong DT, Fuller RW, and Robertson DW (1990). Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm Nordic 2:171-179.